The purpose of this core is to provide a centralized laboratory resource for cryopreservation and distribution of patient samples and to monitor the kinetics of immunologic reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT). Prior to transplantation, peripheral blood mononuclear cells (PBMC), bone marrow and serum or plasma are obtained from all patients enrolled on clinical trials supported by this Program Project. PBMC and plasma or serum are also obtained from normal stem cell donors for these individuals. Following HSCT, PBMC, DNA and plasma samples are cryopreserved at regular intervals. These samples are made available to all of the investigators in this program. Immune reconstitution after HSCT is evaluated through a variety of methods that provide a quantitative assessment of specific lymphocyte populations as well as their level of maturation and function. Quantitative analysis of circulating lymphocytes is determined by multi-parameter flow cytometry with a panel of fluorochrome- conjugated monoclonal antibodies. This is primarily evaluated using fresh samples and semi-automated methods for immunofluorescence analysis of whole blood. Assays of immune function primarily utilize cryopreserved PBMC. Reconstitution of T cell receptor repertoire is examined by the method of TCR Vp spectratyping. Thymic function is evaluated by quantitative PCR measurement of T-cell receptor excision circles (TREC) in PBMC. Reconstitution of T cell immunity to specific target antigens such as CMV and EBV is determined by ELISPOT. Results of each of these assays can be correlated with other parameters of immune function as well as with clinical outcomes. The availability of pre-HSCT samples as well as normal donor samples provides additional control populations and will allow additional comparisons. This core has 3 Specific Aims: 1. To obtain, isolate and cryopreserve mononuclear cells, DNA, RNA, plasma and serum components from patient samples for subsequent study by program investigators. 2. To maintain a computerized inventory of banked samples, assure patient privacy and distribute samples in a timely and equitable fashion to laboratory investigators for experiments proposed in this application. 3. To provide phenotypic and functional measurements of immune reconstitution in peripheral blood, bone marrow and targeted skin biopsies following allogeneic HSCT.

Public Health Relevance

Allogeneic stem cell transplantation provides effective therapy for many patients with hematologic cancers. However, some patients develop toxicities related to engraftment of donor immune cells. This core will be responsible for obtaining blood samples from patients at defined times before and after transplantation and will use these samples to assess the status of immune reconstitution. Patient confidentiality will be maintained and samples will only be obtained from patients who have provided informed consent.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
9P01CA142106-06A1
Application #
7683383
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2009-04-01
Project End
2014-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
6
Fiscal Year
2009
Total Cost
$363,561
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Gartlan, Kate H; Bommiasamy, Hemamalini; Paz, Katelyn et al. (2018) A critical role for donor-derived IL-22 in cutaneous chronic GVHD. Am J Transplant 18:810-820
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Koreth, John; Kim, Haesook T; Lange, Paulina B et al. (2018) Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica 103:522-530
Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V et al. (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128:446-462
Kolupaev, Oleg V; Dant, Trisha A; Bommiasamy, Hemamalini et al. (2018) Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Adv 2:2307-2319
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Zeiser, Robert; Sarantopoulos, Stefanie; Blazar, Bruce R (2018) B-cell targeting in chronic graft-versus-host disease. Blood 131:1399-1405
Blazar, Bruce R; MacDonald, Kelli P A; Hill, Geoffrey R (2018) Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood 131:2651-2660
Lu, Yunjie; Gao, Ji; Zhang, Shaopeng et al. (2018) miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). Cell Death Dis 9:290
Cichocki, Frank; Wu, Cheng-Ying; Zhang, Bin et al. (2018) ARID5B regulates metabolic programming in human adaptive NK cells. J Exp Med 215:2379-2395

Showing the most recent 10 out of 207 publications